Cancer Basics
A plain-language guide to the words, tests, and choices you will hear in the weeks ahead. Read this before the guide for your specific cancer.
Welcome
If you are reading this, you or someone close to you has probably just been told about a cancer diagnosis. Much of what comes next gets explained in unfamiliar words, at a time when it is hard to take anything in.
This guide explains the vocabulary that comes up in almost every cancer conversation. It walks through what cancer is, how it is found, and how it is graded and staged. It also covers the main kinds of treatment, what the follow-up years look like, and some of the harder feelings that come with a cancer diagnosis.
After you read this, your care team will point you to a guide for your specific cancer. The two go together: this one explains the words your team is using, and the other one explains your situation.
How to use this guide. Read it once at your own pace. Highlight the parts that fit your situation and skip the parts that do not. Then bring your questions, and the worksheet in Chapter 13, to your next visit. You are not expected to memorize any of this. Knowing where to look it up later is enough.
What is cancer?
Almost every word you will hear in the weeks ahead comes from one piece of biology.
The basic idea
Every part of your body is made of cells. Cells grow, divide, do their job, and die. Cancer starts when a single cell picks up a set of changes in its DNA that turn off the normal brakes. That cell keeps dividing, and so do its copies. Over time, that line of cells forms a lump or spreads through tissue.
This is why so many cancer words exist. Tumor, grade, stage, spread, targeted therapy, and immune therapy are all about this one process. Each kind of treatment is a different way to stop or remove cells that grow without brakes.
A tumor is not the same as cancer
- A tumor is any abnormal lump or mass.
- A benign tumor can grow but does not invade nearby tissue and does not spread. Common ones include fatty lumps, most uterine fibroids, and most thyroid nodules.
- A malignant tumor is cancer. It can invade nearby tissue and send cells to other places in the body.
- Some tumors fall between the two. You may hear "borderline," "low malignant potential," or "pre-cancer." These need close follow-up.
Cancer is not one disease
Cancer is a family of hundreds of diseases that share the same general behavior. A breast cancer cell and a kidney cancer cell look different under the microscope and respond to different treatments. The kind of cancer you have matters more than the word cancer itself. Your team will name yours.
For most people the answer is no. Most cancers come from random DNA copy errors that build up over a lifetime. Some mix of exposures and inherited risk plays a part too. Even with a clear risk factor like smoking or a known inherited gene change, plenty of people with that same risk never get cancer, and plenty of people with no obvious risk do. Self-blame in the first few weeks is common, and it rarely matches what actually caused the cancer.
How cancer is found
Almost every new cancer diagnosis is made in one of three ways. Knowing which one applies to you helps make sense of the workup that follows.
Three common paths
- Screening. A test in a person who has no symptoms, looking for early cancer in a group at risk. Mammograms, colonoscopies, low-dose lung CT for long-term smokers, and PSA testing for prostate cancer all fall here.
- Symptoms. A new lump, blood in the urine or stool, weight loss you cannot explain, a cough that does not go away, a mole that changes, or pain that does not resolve. These send a person to a clinic, and then to imaging or a biopsy.
- An incidental finding. A scan done for an unrelated reason picks up something. Many kidney cancers and some lung cancers are found this way. In these cases the cancer was already there, and the scan simply happened to look in that direction.
The biopsy is the proof
Imaging can suggest cancer, but only a biopsy proves it. A biopsy is a small sample of tissue or fluid that a pathologist looks at under the microscope. The most common kinds:
- Needle biopsy. A thin needle pulls a small piece of tissue. It is often guided by ultrasound or CT.
- Endoscopic biopsy. A sample taken during a scope, like a colonoscopy or a bladder scope.
- Surgical biopsy. All or part of the area is cut out in surgery.
- Liquid biopsy. A blood test that picks up cancer DNA. It is used more for tracking than for first diagnosis.
Common imaging you will hear about
- CT scan. A fast cross-section X-ray, commonly used for staging.
- MRI. Detailed soft-tissue imaging. Common for brain, spine, prostate, and liver.
- PET/CT. Shows areas with high cell activity. Used for staging and follow-up.
- Ultrasound. A live picture using sound waves. Used to look at the thyroid, breast, kidney, and to guide biopsies.
- Bone scan. Picks up cancer in bone.
A scan can show a suspicious mass and point your team to where to look. The biopsy is what tells your team the cell type, the grade, and the biomarkers. Those results decide which treatments are likely to help. Outside of a few specific situations, such as a kidney mass headed straight to surgery, cancer treatment essentially never starts without one.
Reading your pathology report
The pathology report is one of the most important documents in your chart. Ask for a copy if you do not have one, circle the words you do not understand, and bring it to your next visit so your team can read it with you line by line.
Cell type: where it started
The cell type tells you what kind of cell turned into cancer. It usually matches an organ or a tissue.
- Carcinoma: starts in cells that line organs and surfaces. The most common kind. It has subtypes: adenocarcinoma starts in gland cells (prostate, colon, lung, breast). Squamous cell carcinoma starts in flat lining cells (skin, head and neck). Urothelial carcinoma starts in the bladder lining. Renal cell carcinoma starts in the kidney.
- Sarcoma: starts in connective tissue (bone, muscle, fat, blood vessels).
- Lymphoma: starts in immune cells in the lymphatic system.
- Leukemia: starts in blood-forming cells in the bone marrow.
- Melanoma: starts in pigment cells.
- Germ cell tumor: starts in egg or sperm precursor cells.
Differentiation and grade
Differentiation is how much the cancer cells still look like the tissue they came from. Grade is a score for how aggressive the cells look. The two go together.
- Well differentiated: cells still look a lot like normal cells. Often grow slowly.
- Moderately differentiated: in between.
- Poorly differentiated: cells look quite abnormal. They tend to grow faster.
- Undifferentiated: cells look so abnormal it is hard to tell where they came from. Often grow faster.
Each cancer has its own grade scale. Prostate uses the Gleason score and Grade Group. Kidney uses ISUP grade 1 to 4. Breast uses Nottingham grade 1 to 3. Because each system is scored differently, a grade only makes sense next to the scale it came from, so ask your team what your grade means on its own scale.
Margins, lymphovascular invasion, and biomarkers
- Margin: the cut edge of a removed tumor. A negative margin means no cancer at the edge. A positive margin means cancer cells reach the edge, so some may have been left behind, and your team may suggest more surgery, radiation, or other treatment.
- Lymphovascular or perineural invasion: cancer cells seen in lymph or blood vessels, or along nerves. Not the same as confirmed spread, but it raises the risk of it.
- Biomarkers: tests done on the tumor itself. Examples are HER2 in breast cancer, EGFR in lung cancer, and MSI in colon cancer. BRCA1/2 is another, seen in ovarian, breast, prostate, and pancreatic cancer. These results often decide whether targeted or immune therapy is an option for you.
Grade vs stage
Grade and stage are the two words patients mix up most often when they call the office with questions. They sound alike and often appear in the same sentence on your report. Each answers a different question, and your treatment plan depends on both.
Grade is about the cells
Grade is how aggressive the cancer cells look under a microscope. A pathologist gives the grade. It comes from the biopsy or the surgical specimen. Grade helps predict how the cancer is likely to behave over time.
Stage is about the spread
Stage is how far the cancer has traveled. Your team gives the stage from the imaging, the exam, and any tissue removed at surgery. Stage describes where the cancer is right now: in the organ, in nearby lymph nodes, or in distant places.
A worked example
Two people with kidney cancer:
- Person A. A 3 cm tumor, ISUP grade 4 (high grade), still inside the kidney. High grade, low stage (Stage I). Often curable with surgery. Closer follow-up after.
- Person B. An 8 cm tumor, ISUP grade 2 (low grade), with one positive lymph node. Low grade, higher stage (Stage III). Surgery, plus a talk about extra treatment, plus longer follow-up.
Both situations come through clinic regularly. When your team gives you a grade and a stage, ask what each number means on its own and what the combination means for your case.
An aggressive-looking cancer caught early often has a strong outlook with surgery and close follow-up. A slow-looking cancer that has already spread is still serious, even though the cells look close to normal. The numbers on their own will mislead you. That is why the team always looks at them together with the imaging and the rest of your health.
TNM and stage groups
TNM is the universal shorthand for cancer stage. It is used across almost every solid tumor in the United States and most of the world. Each letter answers a separate question about where the cancer is in the body.
What T, N, and M mean
- T = Tumor. How big is the main tumor and how far has it grown into nearby tissue. Ranges from T0 (none seen) and Tis (carcinoma in situ, on the surface only) up to T4 (largest or most invasive). The exact numbers vary by organ.
- N = Nodes. Has the cancer reached nearby lymph nodes. N0 means no, N1 to N3 mean yes, with rising number or location.
- M = Metastasis. Has the cancer reached distant organs. M0 means no. M1 means yes.
Stage groups
The TNM letters are bundled into a stage group, often a Roman numeral.
- Stage 0: in situ. Cells are present but have not invaded.
- Stage I: small, in the organ.
- Stage II: larger, still in the organ.
- Stage III: spread to nearby lymph nodes or tissue.
- Stage IV: distant spread.
Local, regional, and distant
Your team may also use plainer words.
- Localized: cancer is in the organ where it started, with no signs it has moved. Often Stage I or II.
- Regional: cancer has reached nearby lymph nodes or nearby tissue. Often Stage III.
- Distant or metastatic: cancer has reached far parts of the body, like lung, liver, bone, or brain. Stage IV.
Clinical stage and pathologic stage
You may hear two stages for the same cancer.
- Clinical stage (cTNM): the team's best guess before surgery, based on exam and scans.
- Pathologic stage (pTNM): the more exact stage. It is set after surgery, once the tissue and lymph nodes have been looked at under the microscope.
The pathologic stage usually has more weight when your team thinks about outlook and the next steps. The TNM system itself is set by the American Joint Committee on Cancer (AJCC), along with the world cancer staging body. They update it organ by organ.
The main kinds of treatment
Most treatment plans pull from one, two, or all three of the broad categories below. They are often layered in sequence rather than chosen as alternatives.
Surgery
Surgery removes the cancer. It works best when the cancer is in one place. Today's options often include minimally invasive (laparoscopic or robotic) and open approaches. The goal is full removal with clean margins. Many cancers caught early are cured with surgery alone.
Radiation
Radiation uses high-energy beams to damage cancer DNA so cells cannot keep dividing. It comes in a few forms.
- External beam: aimed at the tumor from outside the body.
- Brachytherapy: radioactive seeds or sources placed inside or next to the tumor.
- Stereotactic body radiation (SBRT): a higher dose, aimed at the tumor with great care. It is given over only a few visits.
Radiation can be the main treatment. It can also be given after surgery to lower the chance of return, or to ease symptoms in advanced cancer.
Systemic therapy
Systemic therapy is treatment that travels through the bloodstream and reaches cancer cells anywhere in the body. The four main kinds:
- Chemotherapy. Drugs that target cells that divide quickly. They kill cancer cells and also affect normal fast-dividing cells (bone marrow, hair, the lining of the gut), which is where the classic side effects come from.
- Targeted therapy. Drugs that aim at specific molecules driving a particular cancer's growth. They only work when the tumor has the target. This is why molecular testing on your tumor matters.
- Hormone therapy. Drugs for cancers that grow in response to hormones. Used in many breast and prostate cancers. The side effects are different from chemotherapy.
- Immunotherapy. Drugs that release the brakes on the immune system so it can find and attack cancer cells. Side effects are different again. The immune system can sometimes attack normal organs, so the team watches for that.
You may also hear other names. Antibody-drug conjugates send chemo to cancer cells more directly. Some drugs are radioactive and stick to cancer. Stem cell and bone marrow transplant are used in some blood cancers. CAR-T cell therapy uses your own immune cells to fight your cancer. Each of these is used in a small group of cancers.
Words around the treatment plan
A few pairs of words come up in almost every cancer planning conversation.
Neoadjuvant and adjuvant
- Neoadjuvant means treatment given before the main therapy, which is often surgery. It can shrink the tumor, make surgery easier, and treat any cells that may have escaped. It also shows the team how the cancer reacts to a drug.
- Adjuvant means treatment given after the main therapy. It aims at any cells that may have escaped before surgery, to lower the chance the cancer comes back.
The same drug can be used in either role.
Curative intent and palliative intent
Intent describes the goal of a treatment plan, not a guarantee.
- Curative intent. The plan is aiming to clear the cancer and keep you cancer-free, ideally for good. Even with curative intent, no team can promise a cure. They mean that is the goal.
- Palliative intent. The plan is aiming to control the cancer, extend life, and protect quality of life when cure is not realistic. Palliative-intent treatment can still be very effective. It often uses many of the same drugs.
Intent changes how much you push through side effects, how often you get scans, and how the team plans the next step. A question you can ask your team: "Is this treatment aimed at curing the cancer, or at controlling it?"
Active surveillance and watchful waiting
Some cancers do not need treatment right away. For these, the first step is often a set plan of regular checks.
- Active surveillance is a planned set of scans, lab tests, and sometimes repeat biopsies. You and your team have a clear plan to start treatment if the cancer changes. It is used in low-risk prostate cancer, small kidney masses in some patients, some thyroid cancers, and some slow blood cancers.
- Watchful waiting is a less structured kind of monitoring, often used when active treatment is not a fit because of age or other illness. Treatment starts only when symptoms appear, and the goal is comfort.
Active surveillance is not the same as doing nothing. For some low-risk cancers, the side effects of treating right away outweigh the small risk of waiting on a set schedule.
After treatment, and scanxiety
After treatment, much of life settles back into a routine. There are stretches of waiting between follow-up scans.
What surveillance looks like
After treatment aimed at cure, you enter a follow-up program. The exact schedule depends on the cancer and the risk, and your team will set yours. Most plans include:
- Regular visits with the cancer team.
- Imaging at set intervals (CT, MRI, PET, bone scans, mammograms).
- Blood markers, when they apply, such as PSA in prostate cancer, CEA in colon cancer, CA-125 in ovarian cancer, and others in some testicular cancers.
- Scopes when they apply (colonoscopy, bladder scope).
Visits are often closer together in the first 2 to 3 years, when most recurrences happen, then spread out. Many programs follow you for 5 to 10 years. Some go on for life.
Recurrence and progression
- Recurrence means the cancer comes back after a period of no detectable disease. It can be local (same place), regional (nearby lymph nodes), or distant (a far organ).
- Progression means the cancer grows or spreads while it is still being treated, or while still being watched with measurable disease. It is the word your team uses when a treatment is no longer holding the cancer in check.
A recurrence often leads to a fresh round of staging and a new plan. Sometimes that plan includes another shot at curative treatment. Progression on one drug usually means switching to a different line of therapy, not the end of options.
Many patients feel a wave of anxiety in the week before a follow-up scan. It has a name: scanxiety. A few practical things make it more tolerable. Scheduling the scan for early in the week shortens the wait. Booking a brief follow-up call within 48 hours of the result keeps a hard number from sitting unread for days. If the anxiety is interfering with sleep, work, or your relationships, talking with a therapist who works with cancer patients often helps. Ask your team for a referral.
Genetic testing, in two kinds
Cancer genetic testing comes in two kinds that get confused with each other regularly. They look at different DNA, on different samples, and answer different questions. Both can matter for the same patient.
Germline testing
Germline testing looks at the DNA you were born with. The sample is blood or saliva. The test checks for inherited changes that raise cancer risk. One example is BRCA1 and BRCA2, linked to breast, ovarian, prostate, and pancreatic cancer. Another is the Lynch syndrome genes, linked to colon, uterine, ovarian, and urinary tract cancers.
A positive germline test has two layers. One is for you: it can change your screening, the choice of treatment, and sometimes your option for risk-reducing surgery. The other is for your blood relatives: they may benefit from testing too.
Somatic (tumor) testing
Somatic testing looks at the DNA inside the tumor itself. The sample is tumor tissue, or sometimes blood from a liquid biopsy. It checks for changes the cancer cells picked up. These changes are not inherited. They are not in the rest of your body.
Tumor testing does three jobs. It helps choose the best targeted drugs for your cancer, and it finds markers that show whether immune therapy may work. It can also show why a drug stopped working, so the team can switch.
Why both can matter
Some changes found in tumor testing turn out to be inherited. Guidelines now suggest that certain tumor results should lead to a follow-up germline test. In metastatic prostate cancer, for example, both kinds of testing are recommended.
A positive germline result has meaning for your blood relatives too. A genetic counselor helps you read the result, plan the next steps, and decide who in the family to tell and how. Before you test, know one legal point: a federal law called GINA blocks health insurance and employers from using your genetic results. It does not cover life, disability, or long-term care insurance.
Reading survival numbers honestly
Almost every patient looks up survival statistics in the first week after diagnosis. Read without any context, the numbers usually cause more worry than they help. Here is what those figures mean, and how to put them next to your own case.
What 5-year relative survival means
This is the number you see most often. It is the share of people with a cancer who are alive five years later, compared to people without that cancer who match for age and other factors. It strips out deaths from unrelated causes.
Say the 5-year relative survival is 80 percent. That means people with the cancer were about 80 percent as likely as a matched person without it to be alive at five years. The figure describes a group of people, not your specific case.
Six things to keep in mind
- The number describes a group. A 70 percent figure does not mean your odds are 70 percent. Your case has its own stage, grade, biology, and health.
- The data is a few years old. Numbers published this year reflect people diagnosed years ago. Newer drugs are not in those figures yet. Today's results are usually a bit better.
- Look at stage-specific numbers. The split between localized, regional, and distant is often huge. Use the version that matches your stage.
- Relative vs overall survival. Relative pulls out deaths that are not from the cancer. For older patients with other health issues, relative is the cleaner cancer-only number.
- Median survival. Half of people live longer, and half live shorter.
- Some people live far longer than the average. Many people do better than the median or the 5-year mark suggests, especially with newer treatments.
Where to look
The clearest sources are the SEER program at the National Cancer Institute, the American Cancer Society, and your own care team. Your team can put any number you find next to your own case.
Trials, palliative care, hospice
Three terms come up in cancer care and get misread regularly.
Clinical trials
Patients often hear "clinical trial" and think it means experimental, a last resort, or untested. That has not matched how cancer research works for a long time now.
- Phase I: early dose-finding studies with small numbers of patients. These were once a last resort, but today they can be a way to get promising new drugs in many advanced cancers.
- Phase II: tests how well the drug works in a defined group.
- Phase III: compares the new approach to current best treatment, often randomly. The big trials behind FDA approvals.
Trials are not only for people out of options; many enroll at first diagnosis. And in most US cancer trials, no one is denied effective treatment. The usual setup compares current best care to current best care plus a new drug. ClinicalTrials.gov is the public registry. Your team's research coordinator knows what is open at your center.
Palliative care and hospice are different
In everyday talk, palliative care and hospice get used to mean the same thing. In cancer care they describe two very different things.
- Palliative care is a kind of care that helps with quality of life and symptoms during a serious illness. It runs alongside your cancer treatment and can start the same day. Palliative teams help with pain, nausea, fatigue, sleep, worry, hard family talks, and choices about care. Studies show that early palliative care helps you feel better and, in some cancers, helps people live longer.
- Hospice is a specific program of comfort care for people who are no longer pursuing treatment for cure or control. It is usually offered when the life expectancy is estimated at 6 months or less. Hospice can happen at home, in a hospice house, or in a hospital. It does not mean death is right around the corner. Many people live longer and more comfortably on hospice than they would have without it.
Your team is bigger than your doctor
Cancer care is rarely the work of one person. A medical oncologist runs systemic therapy, a surgical oncologist does the surgery, and a radiation oncologist runs radiation. A pathologist reads the tissue, and a radiologist reads the scans. A nurse navigator helps you move through the system, and a social worker, a pharmacist, and a genetic counselor may join too. Many cases are also reviewed at a tumor board, where the whole group decides together. You can ask if yours has been.
Questions every patient asks
The questions patients ask most often in the first weeks after diagnosis, with first-pass answers. Your team will tailor each one to your specific situation.
Did I cause this?
For most people, no. Most cancers come from random DNA copy errors that build up over a lifetime, with some part played by exposures and inherited risk. The first weeks of self-blame are nearly universal in clinic, and they rarely match what actually happened in your body.
Am I going to die from this?
Some people eventually will, and many will not. Ask your care team what they think is realistic for your own case.
Should I get a second opinion?
Almost always reasonable. A second look at a major cancer center can confirm the plan, find more options, or open trial doors. A good team does not take offense.
How do I tell my family?
There is no perfect script. Direct words for adults and age-appropriate words for kids work well for most. Many cancer centers have social workers who help.
Do I have to keep working?
This is a personal and financial decision. The Family and Medical Leave Act (FMLA) and short-term disability are options. The cancer center social worker is often the best first call.
Will treatment affect my fertility?
If you are of reproductive age, this question deserves an answer before treatment starts. Sperm banking and egg or embryo banking can sometimes be done if there is time. Ask early.
Should I change my diet, exercise, or take supplements?
A balanced diet, gentle activity when you can, and staying off tobacco and heavy alcohol are all reasonable. Most supplements have no proven benefit, and some get in the way of cancer drugs. Run anything new past your team first.
Is my cancer hereditary? Should my children be tested?
Depends on your cancer type, family history, and genetic test results. Genetic counseling is the right next step.
What about marijuana or CBD?
Some people find it helps with nausea, sleep, or anxiety. Drug interactions and product quality are concerns. Tell your team, especially if you are on immunotherapy or blood thinners.
How am I supposed to feel right now?
Patients describe numbness, anger, fear, sadness, sudden flashes of relief, dark humor, and feeling completely lost, often all in the same week. Talking with a counselor or therapist who works with cancer patients often helps. Ask your team for a referral.
Questions to ask your team
Bring this list to your next visit. These questions are hard to remember on the spot, and a written list makes it more likely each one gets asked.
About my diagnosis
- What kind of cancer do I have?
- What is the grade, and what does that mean for me?
- What is the stage, and what does that mean for me?
- Have you tested the tumor for biomarkers? If so, which?
- Was my case discussed at tumor board, or could it be?
About the plan
- Is this treatment aimed at curing the cancer, or at controlling it?
- What treatment do you recommend first, and why?
- What other reasonable options exist, and what are the trade-offs?
- Are there clinical trials that fit my situation?
- What happens if I decide to wait or watch first?
About side effects and life
- What side effects should I expect? Which are urgent?
- Will this affect my fertility? Should we plan for that now?
- Can I keep working through treatment? What changes?
- Should I see palliative care alongside this plan?
- What does my recovery and follow-up look like over the next year?
About family
- Is genetic counseling something I should consider?
- What might this mean for my children or siblings?
- How do you suggest I tell people in my life?
About money and logistics
- Who is my main contact for questions between visits?
- Is there a nurse navigator or social worker I can meet?
- What help is there for travel, lodging, or costs I have to pay myself?
Words to know
A short reference for the vocabulary in this guide. Mark the ones you keep needing to look up.
- Adjuvant therapy
- Treatment given after the main therapy to lower the chance of return.
- Active surveillance
- A planned program of close monitoring, with a plan to treat if the cancer changes.
- Benign
- Not cancer. Can grow but does not invade or spread.
- Biopsy
- A small sample of tissue or fluid looked at under a microscope.
- Carcinoma
- Cancer that starts in lining cells. The most common kind.
- Chemotherapy
- Drugs that target cells that divide quickly.
- Clinical trial
- A research study that tests a new treatment.
- Curative intent
- Treatment aimed at clearing the cancer.
- Germline mutation
- A DNA change you were born with, in every cell.
- Grade
- How aggressive cancer cells look under the microscope.
- Hospice
- Comfort care for people no longer pursuing cure or control.
- Immunotherapy
- Treatment that helps the immune system attack cancer.
- In situ
- Cancer cells that have not invaded beyond their starting layer.
- Localized
- Cancer still in the organ where it started.
- Lymph nodes
- Small filtering structures. Often the first place cancer spreads.
- Malignant
- Cancer. Able to invade and spread.
- Margin
- The cut edge of a removed tumor, checked for cancer cells.
- Metastasis
- Cancer that has spread to another part of the body.
- Neoadjuvant therapy
- Treatment given before the main therapy to shrink the tumor.
- Palliative care
- Care for quality of life and symptoms, alongside cancer treatment.
- Palliative intent
- Treatment aimed at controlling cancer when cure is not realistic.
- Pathology
- The medical field that looks at tissue to make a diagnosis.
- Progression
- Cancer that grows while it is being treated or watched.
- Recurrence
- Cancer that comes back after a period of no detectable disease.
- Regional
- Cancer that has spread to nearby lymph nodes or tissue.
- Sarcoma
- Cancer that starts in connective tissue.
- Somatic mutation
- A DNA change in the tumor only. Not inherited.
- Stage
- How far the cancer has spread (T, N, M).
- Surveillance
- The follow-up schedule after treatment.
- Targeted therapy
- Drugs aimed at specific molecules driving cancer growth.
- TNM
- The universal staging system: Tumor, Nodes, Metastasis.
- Tumor
- Any abnormal growth, benign or malignant.
- Tumor board
- A team meeting where many specialists review a case together.
- Watchful waiting
- Less structured monitoring, used when active treatment is not a fit.
Sources and further reading
This guide draws on the most widely used cancer references. The list below points to where you can read more, in patient-friendly language.
- National Cancer Institute (NCI): What Is Cancer? cancer.gov
- NCI: Cancer Staging. cancer.gov
- American Cancer Society: Understanding Your Pathology Report. cancer.org
- American Joint Committee on Cancer (AJCC) Staging System. facs.org
- NCI SEER Cancer Statistics. seer.cancer.gov
- NCI: Genetic Testing for Inherited Cancer Susceptibility Syndromes. cancer.gov
- NCI: BRCA Gene Mutations. cancer.gov
- Get Palliative Care: What Is Palliative Care? getpalliativecare.org
- ClinicalTrials.gov. clinicaltrials.gov
- NCCN Guidelines for Patients. nccn.org/patients
- CancerCare (psychosocial and practical support). cancercare.org
- National Society of Genetic Counselors (find a counselor). nsgc.org
About this guide. Written by the WellPrept Clinical Team. Designed as a primer to be read alongside the guide for your specific cancer, not as a replacement for your care team's guidance. Always work through your own situation with your team.